Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.
Jaime Schneider, MD, PhD
Advertisement
Articles by Jaime Schneider, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
3
Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability
4
Dr O’Malley on What to Reach for Outside of a Clinical Trial in Platinum-Resistant Ovarian Cancer
5